Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn’s Disease: A Population-Based Cohort Study

References

• Everhov AH, Halfvarson J, Myrelid P, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154(3):518–28 e15. doi:10.1053/j.gastro.2017.10.03429102619
   PubMed Web of Science ®Google Scholar
• Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25:1896–1905. doi:10.1093/ibd/izz05930934053
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32(10):1228–1239. doi:10.1111/apt.2010.32.issue-1020955442
   PubMed Web of Science ®Google Scholar
• Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study. Aliment Pharmacol Ther. 2010;31(12):1276–1285. doi:10.1111/j.1365-2036.2010.04303.x20298497
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011;33(5):541–550. doi:10.1111/j.1365-2036.2010.04568.x21223344
   PubMed Web of Science ®Google Scholar
• Panaccione R, Loftus EV Jr, Binion D, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn’s disease: results of the adalimumab in Canadian subjects with moderate to severe Crohn’s disease (ACCESS) trial. Can J Gastroenterol. 2011;25(8):419–425. doi:10.1155/2011/72481321912766
   PubMed Web of Science ®Google Scholar
• Binion DG, Louis E, Oldenburg B, et al. Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysis. Can J Gastroenterol. 2011;25(9):492–496. doi:10.1155/2011/93819421912760
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Brynskov J, Thomsen OO, et al. Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in Crohn’s disease. J Crohns Colitis. 2015;9(11):1032–1042. doi:10.1093/ecco-jcc/jjv13926245216
   PubMed Web of Science ®Google Scholar
• Louis E, Lofberg R, Reinisch W, et al. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn’s disease: results from the CARE trial. J Crohns Colitis. 2013;7(1):34–43. doi:10.1016/j.crohns.2012.02.01722480772
   PubMed Web of Science ®Google Scholar
• Saro C, Ceballos D, Munoz F, et al. Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab. Revista Espanola Enfermedades Digestivas. 2017;109(2):122–129. doi:10.17235/reed.2016.4600/2016
   Web of Science ®Google Scholar
• Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31(2):125–136. doi:10.1007/s10654-016-0117-y26769609
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Svedberg P, Olen O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423–437. doi:10.1007/s10654-019-00511-830929112
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–667. doi:10.1007/s10654-009-9350-y19504049
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi:10.1186/1471-2458-11-45021658213
   PubMed Web of Science ®Google Scholar
• SWIBREG årsrapport för 2015; 916, 2019 Available from: http://www.swibreg.se/wp-content/uploads/2015/11/SWIBREG_Arsrapport_och_verksamhet_2015.pdf. Accessed 221, 2020.
   Google Scholar
• Wettermark B, Hammar N, Fored CM, et al. The new Swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735. doi:10.1002/(ISSN)1099-155716897791
   PubMed Web of Science ®Google Scholar
• Olen O, Askling J, Sachs MC, et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014. Gut. 2019;69(3):453–61.31092591
   PubMed Web of Science ®Google Scholar
• MIDAS Database. Försäkringskassan; [ cited 2015]. Available from: http://www.forsakringskassan.se.. Accessed 221, 2020.
   Google Scholar
• Everhov AH, Sachs MC, Malmborg P, et al. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastroenterol. 2019;54(1):1–9.30650313
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Mahl M, Sachs MC, et al. Fracture risk in patients with inflammatory bowel disease: a nationwide population-based cohort study from 1964 to 2014. Am J Gastroenterol. 2019;114(2):291–304. doi:10.14309/ajg.000000000000006230730858
   PubMed Web of Science ®Google Scholar
• Everhov AH, Khalili H, Askling J, et al. Work loss before and after diagnosis of Crohn’s disease. Inflamm Bowel Dis. 2018;25(7):1237–1247.
   Web of Science ®Google Scholar
• Everhov AH, Khalili H, Askling J, et al. Sick leave and disability pension in prevalent patients with Crohn’s disease. J Crohns Colitis. 2018;12:1418–1428. doi:10.1093/ecco-jcc/jjy12330165593
   PubMed Web of Science ®Google Scholar
• Spekhorst LM, Oldenburg B, van Bodegraven AA, et al. Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease. World J Gastroenterol. 2017;23(46):8182–8192. doi:10.3748/wjg.v23.i46.818229290654
   PubMed Web of Science ®Google Scholar
• Ramos A, Calvet X, Sicilia B, et al. IBD-related work disability in the community: prevalence, severity and predictive factors. A cross-sectional study. United Eur Gastroenterol J. 2015;3(4):335–342. doi:10.1177/2050640615577532
   Web of Science ®Google Scholar
• Martinsson ES, Josefsson M, Ek AC. Working capacity and quality of life after undergoing an ileostomy. J Adv Nurs. 1991;16(9):1035–1041. doi:10.1111/j.1365-2648.1991.tb03363.x1834716
   PubMed Web of Science ®Google Scholar
• Mandel MD, Balint A, Lovasz BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ. 2014;15(Suppl 1):S121–8. doi:10.1007/s10198-014-0613-524832845
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Weber LR, Knox JF, et al. Permanent work disability in Crohn’s disease. Am J Gastroenterol. 2008;103(1):154–161. doi:10.1111/j.1572-0241.2007.01561.x18076736
   PubMed Web of Science ®Google Scholar
• Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn’s disease. J Clin Gastroenterol. 2005;39(5):390–395. doi:10.1097/01.mcg.0000159220.70290.4115815207
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2(11):785–792. doi:10.1016/S2468-1253(17)30248-028838644
   PubMed Web of Science ®Google Scholar
• Nordgren SR, Fasth SB, Oresland TO, Hulten LA. Long-term follow-up in Crohn’s disease. Mortality, morbidity, and functional status. Scand J Gastroenterol. 1994;29(12):1122–1128. doi:10.3109/003655294090948987886401
   PubMed Web of Science ®Google Scholar